PTPN11 and cancer: To investigate the sensitivity of various FGFR-dependent cell lines to allosteric SHP2 inhibition, we examined the correlation between sensitivity to SHP099 and sensitivity to a variety of RTK inhibitors in a high-throughput compound profiling of cancer cell lines as previously described [18, 19].